Insider Trading February 20, 2026

Talphera CFO Buys $36,553 of Stock, Receives 260,000-Share Option Grant

Raffi Asadorian purchased 45,000 shares and surrendered a small parcel to cover taxes; options granted are exercisable at $0.8123 through 2036.

By Caleb Monroe TLPH
Talphera CFO Buys $36,553 of Stock, Receives 260,000-Share Option Grant
TLPH

Talphera Chief Financial Officer Raffi Asadorian reported purchasing 45,000 shares on February 12 at $0.8123 per share for a total of $36,553, while surrendering 3,891 shares to cover tax obligations and receiving options to buy 260,000 shares exercisable at $0.8123 and expiring February 11, 2036. The company’s stock was trading around $0.78 and carried a market capitalization of $36.09 million at the time of the transaction.

Key Points

  • CFO Raffi Asadorian personally bought 45,000 Talphera shares for $36,553 and was granted options to buy 260,000 shares at $0.8123.
  • A small block of 3,891 shares was surrendered between February 10 and February 14 to cover tax obligations, recorded at prices from $0.7934 to $0.8361.
  • At the time of the reported purchase the stock traded at $0.78 and Talphera’s market capitalization was $36.09 million - InvestingPro analysis flagged the stock as appearing undervalued.

Talphera, Inc. (NASDAQ:TLPH) disclosed insider activity by its chief financial officer, Raffi Asadorian, in filings with the U.S. Securities and Exchange Commission.

According to a Form 4 filing, Asadorian purchased 45,000 shares of the company’s common stock on February 12 at an exercise price of $0.8123 per share, representing a total cash outlay of $36,553. The company’s shares were trading at $0.78 at the time, and Talphera reported a market capitalization of $36.09 million.

The filing also shows that Asadorian surrendered 3,891 shares between February 10 and February 14 to satisfy tax withholding obligations. Those surrendered shares were reported at prices ranging from $0.7934 to $0.8361 and had an aggregate value of $3,128.

In the same filing, Asadorian was granted options to purchase 260,000 shares of Talphera common stock on February 12. The options are exercisable at $0.8123 per share and carry an expiration date of 2036-02-11.

Separately, InvestingPro analysis included with the filing noted that the stock appears undervalued at current levels. For readers seeking a deeper look at valuation and financial metrics, a Pro Research Report covering this issuer is available, along with reports for more than 1,400 other U.S. equities.


Context and immediate facts

  • Purchase: 45,000 shares on February 12 at $0.8123 per share - total $36,553.
  • Surrender: 3,891 shares surrendered between February 10 and February 14 to cover taxes; prices between $0.7934 and $0.8361 - total $3,128.
  • Option grant: 260,000 options granted on February 12, exercisable at $0.8123, expiring 2036-02-11.
  • Market snapshot: stock trading at $0.78 and company market capitalization reported as $36.09 million.

Notes on interpretation

The SEC Form 4 provides the transaction-level details above; no additional commentary or conclusions are included in the filing itself. The InvestingPro observation that the share price appears undervalued is noted in the filing materials referenced.

Risks

  • The disclosed purchase amount is modest in absolute terms relative to broader market activity, which may limit its signal to investors - this impacts small-cap equities and investor interpretation in the stock market.
  • Shares were surrendered to cover tax obligations, reducing the CFO’s net shareholdings and potentially affecting simple interpretations of insider accumulation - this affects corporate insider ownership metrics.
  • Options granted carry a long-dated expiration (2036-02-11) and an exercise price of $0.8123; their future value depends on future stock performance, introducing long-term execution risk for holders and investors.

More from Insider Trading

Beam Therapeutics CMO Sells Shares to Meet Tax Withholding After RSU Vesting Apr 6, 2026 Altimmune Director Increases Stake with $31,349 Purchase Apr 6, 2026 Beam Therapeutics CEO Sells $739,317 in Stock to Cover RSU Taxes; Company Updates Clinical Data Apr 6, 2026 Lands’ End CFO Disposes of Shares Amid Stock Volatility; Company Posts Q4 Miss and Approves Buyback Apr 6, 2026 UWM Holdings Executives, Major Shareholder Dispose of $7.4M in Stock Apr 6, 2026